Pfizer (PFE) Revenue (2009 - 2025)

Pfizer (PFE) has 17 years of Revenue data on file, last reported at $62.6 billion in FY2025.

• Revenue for Q1 2026 came in at $2.3 billion, up 10.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.5 billion (down 20.35% YoY), and the FY2025 annual result was $62.6 billion, up 646.05% from the prior year.
• Revenue rose to $62.6 billion in FY2025 per PFE's latest filing, from $8.4 billion in the prior year.
• Over five years, Revenue peaked at $81.3 billion in FY2021 and troughed at $8.4 billion in FY2024.
• A 5-year average of $30.5 billion and a median of $13.9 billion in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2025: Revenue plunged 89.5% in 2022, then soared 646.05% in 2025.
• A 5-year view of Revenue shows it stood at $81.3 billion in 2021, then sank by 89.5% to $8.5 billion in 2022, then surged by 597.59% to $59.6 billion in 2023, then plunged by 85.92% to $8.4 billion in 2024, then soared by 646.05% to $62.6 billion in 2025.
• Business Quant data shows PFE's Revenue at $62.6 billion in FY2025, $8.4 billion in FY2024, and $14.3 billion in FY2024.